COLLEGIUM PHARMACEUTICAL, INC.

(COLL)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
16.36 USD   +2.38%
05/17Collegium to Participate in H.C. Wainwright Global Investment Conference
GL
05/13COLLEGIUM PHARMACEUTICAL, INC Financial Statements and Exhibits (form 8-K/A)
AQ
05/10COLLEGIUM PHARMACEUTICAL : Q1 Earnings Snapshot
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Collegium Pharmaceutical : Announces Settlement Framework to Resolve Pending Opioid-Related Litigation - Form 8-K

12/28/2021 | 08:07am EDT

Collegium Announces Settlement Framework to Resolve Pending Opioid-Related Litigation

STOUGHTON, Mass., December 28, 2021 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the execution of a settlement framework to resolve all 27 pending opioid-related lawsuits brought against the Company by cities, counties, and other subdivisions in the United States. The settlement framework provides for the Company to pay an amount not to exceed $2,750,000 in exchange for the dismissal, with prejudice, of all 27 pending cases and a release from liability related to the dismissed cases. The Company entered into the settlement framework, which is subject to approval by all parties of a final settlement agreement, to efficiently resolve this litigation, and the framework is not an admission of any liability or wrongdoing.

"We are pleased to be in a position to resolve these cases and move forward. We remain committed to our mission of being the leader in responsible pain management," said Shirley Kuhlmann, Executive Vice President, General Counsel of Collegium.

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium's headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company's website at www.collegiumpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding the potential resolution of certain litigation matters and the Company's plans to continue to defend against future litigation. Any forward-looking statements in this press release could be affected by risks and uncertainties relating to a number of factors, including the litigation strategy and preferences of the plaintiffs that have brought lawsuits against the Company and developments in the opioid industry litigation broadly. These and other risks are described under the heading "Risk Factors" in our most recent Quarterly Report on Form 10-Q and subsequent filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:
Alex Dasalla

Head of Investor Relations and Corporate Communications

Adasalla@collegiumpharma.com

Disclaimer

Collegium Pharmaceutical Inc. published this content on 28 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 December 2021 13:06:02 UTC.


© Publicnow 2021
All news about COLLEGIUM PHARMACEUTICAL, INC.
05/17Collegium to Participate in H.C. Wainwright Global Investment Conference
GL
05/13COLLEGIUM PHARMACEUTICAL, INC Financial Statements and Exhibits (form 8-K/A)
AQ
05/10COLLEGIUM PHARMACEUTICAL : Q1 Earnings Snapshot
AQ
05/10TRANSCRIPT : Collegium Pharmaceutical, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/10COLLEGIUM PHARMACEUTICAL, INC Management's Discussion and Analysis of Financial Condit..
AQ
05/10COLLEGIUM PHARMACEUTICAL, INC : Results of Operations and Financial Condition, Regulation ..
AQ
05/10Collegium Reports First Quarter 2022 Financial Results
GL
05/10Collegium Pharmaceutical, Inc. Reports Earnings Results for the First Quarter Ended Mar..
CI
04/26Collegium to Host Conference Call to Discuss First Quarter 2022 Financial Results
AQ
04/13COLLEGIUM PHARMACEUTICAL, INC : Financial Statements and Exhibits (form 8-K)
AQ
More news
Analyst Recommendations on COLLEGIUM PHARMACEUTICAL, INC.
More recommendations
Financials (USD)
Sales 2022 457 M - -
Net income 2022 22,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 28,8x
Yield 2022 -
Capitalization 556 M 556 M -
Capi. / Sales 2022 1,22x
Capi. / Sales 2023 0,98x
Nbr of Employees 152
Free-Float 92,1%
Chart COLLEGIUM PHARMACEUTICAL, INC.
Duration : Period :
Collegium Pharmaceutical, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COLLEGIUM PHARMACEUTICAL, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 16,36 $
Average target price 28,86 $
Spread / Average Target 76,4%
EPS Revisions
Managers and Directors
Joseph J. Ciaffoni President, Chief Executive Officer & Director
Colleen Tupper Chief Financial Officer & Executive Vice President
Michael Thomas Heffernan Chairman
Scott Sudduth Executive Vice President-Technical Operations
Thomas B. Smith Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
COLLEGIUM PHARMACEUTICAL, INC.-12.42%556
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707